Can Fite Biopharma Aktie [WKN DE: A1W6SX / ISIN: US13471N1028]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Can Fite Biopharma Ltd (spons. ADRs)

28.06.24		Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix (Businesswire)
24.06.24		Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver (Businesswire)
10.06.24		Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study (Businesswire)
05.06.24		Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study (Businesswire)
29.05.24		Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases (Businesswire)
27.05.24		Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024 (Businesswire)
23.05.24		Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on June 6 (Businesswire)
13.05.24		Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study (Businesswire)
09.05.24		Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study (Businesswire)
06.05.24		Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602 (Businesswire)
25.04.24		Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal (Businesswire)
15.04.24		Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH (Businesswire)
03.04.24		Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients (Businesswire)
11.03.24		Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference (Businesswire)
28.02.24		Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada (Businesswire)
30.01.24		Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication (Businesswire)
29.01.24		Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study (Businesswire)
20.12.23		The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies (Businesswire)
18.12.23		Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan (Businesswire)
04.12.23		Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development (Businesswire)
30.11.23		Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update (Businesswire)
21.11.23		Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson (Businesswire)
01.11.23		Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track (Businesswire)
30.10.23		Can Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action (Businesswire)
26.10.23		Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs (Businesswire)
09.10.23		Can-Fite to Share its Rare Genetic Disease Lowe Syndrome Novel Treatment with Orphan Drug Japanese Companies (Businesswire)
27.09.23		Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR) (Businesswire)
07.09.23		Can-Fite to Share with Investors Latest Oncology and Rare Genetic Disease Developments at the H.C. Wainwright 25th Annual Conference (Businesswire)
31.08.23		Can-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical Studies (Businesswire)
24.08.23		Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome (Businesswire)
18.08.23		Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis (Businesswire)
17.07.23		Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation (Businesswire)
07.07.23		Can-Fite to Present at the Emerging Growth Conference on July 13, 2023 (Businesswire)
29.06.23		Can-Fite Receives U.S. FDA’s Go Ahead for Piclidenoson Psoriasis Registration Plan (Businesswire)
13.06.23		Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson (Businesswire)
02.06.23		Can-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in Boston (Businesswire)
01.06.23		Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update (Businesswire)
30.05.23		Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO) (Businesswire)
15.05.23		Can-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023 (Businesswire)
09.05.23		Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients (Businesswire)
02.05.23		Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists (Businesswire)
24.04.23		Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization (Businesswire)
10.04.23		Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment (Businesswire)
30.03.23		Can-Fite Reports 2022 Financial Results & Provides Clinical Update (Businesswire)
16.03.23		Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and Namodenoson (Businesswire)
13.03.23		Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting (Businesswire)
14.02.23		Novel Approach to Treating Advanced Liver Cancer with Namodenoson Published in Leading Scientific Journal: 12-Month Survival of 44% for Namodenoson vs. 18% for Placebo (Businesswire)
24.01.23		Can-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies—A Patent Has Been Filed (Businesswire)
11.01.23		Can-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private Placement (Businesswire)
10.01.23		Can-Fite Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; FDA Submission to Follow (Businesswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Bitcoin als Chance: MicroStrategy-Chef fordert Microsoft zu mutigem Schritt auf

CompuGroup-Aktie mit zweistelligem Plus: CVC bestätigt Akquisition

Bayer-Aktie erholt sich weiter: Glyphosat-Fehlprozess in USA

Neue Kooperationsvereinbarung: Palantir-Aktie erreicht neues Rekordhoch - und sackt dann ab

Generative KI: Warum der NVIDIA-CEO auf Accenture setzt

voestalpine-Aktie gewinnt: Wiener Privatbank senkt Kursziel

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	11.12.2024 15:48
Kaufwert:	EUR
	Hinzufügen Speichern